Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 3Carcinoma, Renal Cell 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Solid Tumor, Adult 1Solid Tumor 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Neoplasm Metastasis 1Myoepithelioma 1Liposarcoma, Myxoid 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1Fibrosarcoma 1Disorders of Sex Development 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × pazopanib × Clear all
NCT06816771 2025-02-10

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡